Global Market:
Biopharmaceuticals Market Trends & Competition
R&D Competition, Company R&D Activity & Strategy
and Outlook, 2009-2013
Published by MRG, Inc. and Fuji-Keizai
June 2010, 172 pages
Hard Copy Print Edition $1,495 USD
PDF Single-Departmental License $2,295 USD
PDF Corporate-Wide License $3,495 USD
California orders please add 9.25% sales tax
To order click here or contact Rob Smith at rsmith@mrgco.com
Executive Summary
Today’s pharmaceutical industry is shifting toward biopharmaceuticals at a drastic speed. In 2009, sales of biopharmaceutical drugs accounted for 13% of the total sales of pharmaceuticals. And today, biopharmaceuticals account for 25% of all pharmaceuticals in the development pipeline. We expect that biopharmaceuticals will maintain double digit growth in the years to come, and form a rapidly growing market.
Eying this dramatically expanding market, companies are expanding biopharmaceutical discovery and development, and becoming active in M&A activities including involvement in bio-ventures. As a result, competition is becoming increasingly fierce.
In this study, we describe and report on the current state and future trends of biopharmaceutical drugs in the global market, including:
- Market Overview
- Worldwide Biopharmaceutical Drug Market Trends, 2009-2013
- U.S. Biopharmaceutical Drug Market Trends
?EU.S. Sales of Biopharmaceutical Drugs by Disease Category, 2009-2013
?ENew Drug Market Entries by Disease Category, 2009-2013
?EManufacturers’ Share by Disease Category
- Worldwide Innovative Biopharmaceutical Dug Development by Disease Category
?ENew Drug Pipelines by Disease Category
?ENew Players to Enter the Market by Disease Category
?EBeyond the Pipeline: Hot Categories and Players’ Product Development Strategy
- Worldwide Biopharmaceutical Drug Strategies by Major Company
?EMajor Alliances, M&A and IP
?EWorldwide Biopharmaceutical Drug Strategies by Major Company
?EWorldwide Biopharmaceutical Drug R&D by Major Company
?EPatents, Business Development & Challenges for Worldwide Biopharmaceutical Drug by Major Company
- Important Findings and Suggestions for Business Opportunities
Disease Categories:
Alzheimer’s disease, Anemia, Arthritis, Asthma, Cancer, CAPS, Diabetes, Fabry disease, Gaucher’s disease, Growth hormone deficiency, Hepatitis C, HIV, Lupus, Multiple sclerosis, Neutropenia, Osteoporosis, Parkinson’s disease, Transplant rejection, Ulcerative colitis, Vaccines, Other conditions.
Major Companies:
Abbott Laboratories, AMBiS, Amgen, Bayer, Biogen Idec, Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Elan, Eli Lilly, Genetech, Genzyme, GlaxoSmithKline, Hayashi Kasei Co., Ltd., Human Genome Sciences, Johnson & Johnson, Katakura Industries Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Merck, Merck Serono, Neosilk Co., Ltd., Novartis, Novo Nordisk, Oriental Yeast Co., Ltd. Pfizer, Regeneron, Roche, Sanofi-Aventis, Shionogi & Co., Ltd., Shire, Swedish Orphan Biovitrum, Takeda Pharmaceutical Co., Ltd., Toyobo Co., Ltd., UCB Pharma.
Table of Contents
| 1 |
Market Overview |
| 1.1 |
Worldwide Biopharmaceutical Drug Market
|
| 1.2 |
Noteworthy Biopharmaceutical Drug |
| 1.3 |
Worldwide Biopharmaceutical Drug R&D |
| 1.4 |
Noteworthy Biopharmaceutical Drug Company for R&D Expenditure |
| |
|
| 2 |
Worldwide Biopharmaceutical Drug Market Trends, 2009-2013 |
| 2.1 |
Worldwide Total Biopharmaceutical Drug Market by Company, 2009 |
| 2.2 |
Worldwide Total Biopharmaceutical Drug Market by Disease Category, 2009-2013 |
| 2.3 |
Worldwide Total Biopharmaceutical Drug Market by Branded Product, 2009-2013 |
| 2.4 |
Worldwide Total Biopharmaceutical Drug Market by Region, 2009-2013 |
| |
|
| 3 |
U.S. Biopharmaceutical Drug Market, 2009-2013 |
| 3.1 |
Overview |
| 3.1.1 |
Industry & Market Current Trends |
| 3.1.2 |
Industry Spending for Biopharmaceutical R&D |
| 3.1.3 |
U.S. Prescription Volume for Biopharmaceuticals |
| 3.2 |
U.S. Sales of Biopharmaceuticals Drugs |
| 3.2.1 |
U.S. Sales of Biopharmaceutical Drugs by Disease Category |
| 3.2.2 |
U.S. Sales of Biopharmaceutical Drugs by Company |
| 3.2.3 |
U.S. Sales of Biopharmaceutical Drugs by 20 Disease Categories
Common Research Items:
U.S. Sales of Biopharmaceutical Drugs, 2009
U.S. Market Share of Biopharmaceutical Players, 2009
U.S. Sales of Biopharmaceutical Drugs, 2009-2013
U.S. Sales Growth of Biopharmaceutical Companies, 2009-2013
|
| 3.2.3.1 |
Alzheimer's Disease |
| 3.2.3.2 |
Anemia |
| 3.2.3.3 |
Arthritis |
| 3.2.3.4 |
Asthma |
| 3.2.3.5 |
Cancer |
| 3.2.3.6 |
Cryopyrin-Associated Periodic Syndrome (CAPS) |
| 3.2.3.7 |
Diabetes |
| 3.2.3.8 |
Fabry Disease |
| 3.2.3.9 |
Gaucher's Disease |
| 3.2.3.10 |
Growth Hormone Deficiency |
| 3.2.3.11 |
Hepatitis C |
| 3.2.3.12 |
HIV |
| 3.2.3.13 |
Lupus |
| 3.2.3.14 |
Multiple Sclerosis |
| 3.2.3.15 |
Neutropenia |
| 3.2.3.16 |
Osteoporosis |
| 3.2.3.17 |
Parkinson's Disease |
| 3.2.3.18 |
Transplant Rejection |
| 3.2.3.19 |
Ulcerative Colitis
|
| 3.2.3.20 |
Vaccines |
| 3.2.3.21 |
Other Conditions |
| 3.3 |
Issues and Sales Drivers |
| |
|
| 4 |
Worldwide Innovative Biopharmaceutical Drug Development by Disease Categories |
| 4.1 |
New Drug Pipelines and Players for Future Growth by 20 Disease Categories |
| 4.1.1 |
Alzheimer's Disease - 4.1.21 Other Conditions |
| 4.2 |
New Players to Enter the Market by 20 Disease Categories |
| 4.2.1 |
Alzheimer's Disease - 4.1.21 Other Conditions |
| 4.3 |
Beyond the Pipeline: Hot Categories and Players' Product Development Strategy |
| |
|
| 5 |
Worldwide Biopharmaceutical Strategy by Major Company
|
| 5.1 |
Major Alliances, M&A and IP |
| 5.2 |
Worldwide Biopharmaceutical Drug Strategies by Company |
| 5.2.1 |
Abbott Laboratories |
| 5.2.2 |
Amgen |
| 5.2.3 |
Bayer |
| 5.2.4 |
Biogen Idec |
| 5.2.5 |
Bristol-Myers Squibb |
| 5.2.6 |
Chugai Pharmaceutical Co., Ltd. |
| 5.2.7 |
Daiichi Sankyo Co. Ltd. |
| 5.2.8 |
Elan |
| 5.2.9 |
Eli Lilly |
| 5.2.10 |
Genetech |
| 5.2.11 |
Genzyme |
| 5.2.12 |
GlaxoSmithKline |
| 5.2.13 |
Humane Genome Sciences |
| 5.2.14 |
Johnson & Johnson |
| 5.2.15 |
Kyowa Hakko Kirin Co., Ltd. |
| 5.2.16 |
Merck |
| 5.2.17 |
Merck Serono |
| 5.2.18 |
Novartis |
| 5.2.19 |
Novo Nordisk |
| 5.2.20 |
Pfizer |
| 5.2.21 |
Regeneron |
| 5.2.22 |
Roche |
| 5.2.23 |
Sanofi-Aventis |
| 5.2.24 |
Shire |
| 5.2.25 |
Swedish Orphan Biovitrum |
| 5.2.26 |
Takeda Pharmaceutical Co., Ltd. |
| 5.2.27 |
UCB |
| 5.3 |
Worldwide Biopharmaceutical Drug R&D by Major Company |
| 5.3.1 |
Abbott Laboratories - 5.3.34 UCB Pharma (Total 34 Companies) |
| 5.4 |
Patents, Business Development & Challenges for Worldwide Biopharmaceutical Drug Major Company |
| 5.4.1 |
Abbott Laboratories - 5.4.28 UCB (Total 28 Companies) |
| |
|
| 6 |
Important Findings and Suggestions/Recommendations for Business Opportunities |
| |
|
| 7 |
Appendix |
| 7.1 |
Selected Companies Mentioned in this Report
|
Table of Figures
| Figure 2-1: |
Worldwide Market Share of Top 15 Manufacturers of Biopharmaceutical Drugs, 2009 |
| Figure 3-1: |
U.S. Market Share of 15 Manufacturers of Biopharmaceutical Drugs, 2009 |
Table of Tables
| Table 1-1: |
Worldwide Biopharmaceutical Drug vs. Medical Drug |
| Table 1-2: |
Worldwide Biopharmaceutical Drug vs. Medical Drug by Region |
| Table 1-3: |
Biopharmaceutical Drug R&D Expenditure by Region |
| Table 1-4: |
Top 10 Company R&D Expenditure for Biopharmaceutical Drug |
| Table 2-1: |
Global Sales of Biopharmaceutical Drugs by 25 Companies, 2009 |
| Table 2-2: |
Worldwide Sales of All Biopharmaceutical by 20 Categories, 2009-2013 |
| Table 2-3: |
Worldwide Sales of All Biopharmaceutical by 109 Branded Products, 2009-2013 |
| Table 2-4: |
Worldwide Sales of All Biopharmaceuticals by World Region, 2009-2013 |
| Table 3-1: |
U.S. Sales of Biopharmaceuticals by 20 Categories, 2009-2013 |
| Table 3-2: |
U.S. Sales of Biopharmaceutical Drugs by 23 Companies, 2009 |
| Table 4-1: |
At Glance |
| Table 5-1: |
Major Biotech Alliances, 2009 |
| Table 7-1: |
Major Biopharmaceutical Companies |
Global Market: Biopharmaceuticals Market Trends & Competition (June 2010) is 172 pages. Hard copy edition for $1,495.00 USD, a PDF single-departmental license for $2,295.00 USD, and a pdf corporate license for $3,495.00.
For more information or to order the report, contact Rob Smith at 1-408-453-5553
or rsmith@mrgco.com.
Order Form
|
